UNSPSC 51143904: Deanol aceglumate

This classification denotes a cns stimulant with the molecular formula C7H11NO5.C4H11NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2PP737Z523, chemically known as glutamic acid, n-acetyl-, compd. with 2-(dimethylamino)ethanol (1:1), l- but more generally known as deanol aceglumate, which bears US NIH Compound Identifier 71125. European Medicines Agency schedules Deanol aceglumate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06926MIG.

UNSPSC 51143904 Deanol aceglumate is a Commodity code that in recent state and local procurement activity does not align with its nominal pharmaceutical ingredient scope. The three recent opportunities tagged to this code—Seminole County's procurement of naloxone and drug deactivation systems, the Texas HHS Commission's exploratory RFI on direct-to-manufacturer pharmacy programs, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products—represent broader pharmaceutical, OTC, and pharmacy benefit management procurement rather than the specific active pharmaceutical ingredient named by the code. State and local health agencies, cooperative purchasing alliances, and health and human services commissions are the primary issuing bodies pursuing opportunities under this code classification, though the mismatch between code and actual commodity suggests either inconsistent categorization or a data tagging error in the source records.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 (due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and wholesaler channels, designed to inform a future formal RFP. MMCAP, administered by the Minnesota Department of Administration, released an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products through three authorized wholesalers, with awarded vendors effective July 1, 2026 and a two-year initial term. The code shows active procurement but limited alignment with its stated commodity definition, warranting verification of correct UNSPSC classification before pursuing opportunities.